Top Qs
Timeline
Chat
Perspective
ADB-FUBINACA
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
ADB-FUBINACA (ADMB-FUBINACA[2]) is a designer drug identified in synthetic cannabis blends in Japan in 2013.[3][4] In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration.[5]
Remove ads
The name is an acronym for N-(1-Amino-3,3-Dimethyl-1-oxoButan-2-yl)-1-(4-FlUoroBenzyl)-1H-INdAzole-3-CarboxAmide.
The (S)-enantiomer of ADB-FUBINACA is described in a 2009 Pfizer patent[6] and has been reported to be a potent agonist of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3.5 nM, respectively.[6][7] ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.
An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.
Remove ads
Side effects
One death through coronary arterial thrombosis has been linked to ADB-FUBINACA intoxication.[8]
Metabolism
Twenty-three ADB-FUBINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Major metabolic pathways were alkyl and indazole hydroxylation, terminal amide hydrolysis, subsequent glucuronide conjugations, and dehydrogenation.[9]
Legality
In the United States, ADB-FUBINACA is a Schedule I controlled substance.[10]
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads